Logic Gated CAR T Reports Durable Isolated Responses

Company A2 Biotherapeutics Event Type Clinical follow-up (SITC) Modality Logic-gated (Tmod) CAR-T Asset A2B694 (MSLN, autologous); A2B543; A2B395 (EGFR, allogeneic) Target Mesothelin with HLA-A*02 blocker; EGFR Disease Area Solid tumors (NSCLC, anal cancer, head and neck cancer) Summary A2 Biotherapeutics provided November 3 follow-up from…